Get the Stockscreener App
0.71
4.41%
0.03
Pavmed Inc stock is traded at $0.71, with a volume of 18,065.
It is up +4.41% in the last 24 hours and down -7.02% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$0.68
Open:
$0.67
24h Volume:
18,065
Relative Volume:
0.11
Market Cap:
$12.31M
Revenue:
$4.03M
Net Income/Loss:
$24.32M
P/E Ratio:
-0.1651
EPS:
-4.3008
Net Cash Flow:
$-45.76M
1W Performance:
+4.41%
1M Performance:
-7.02%
6M Performance:
-31.07%
1Y Performance:
-63.96%
1-Day Range:
$0.67
$0.7135
1-Week Range:
$0.638
$0.7449
52-Week Range:
$0.55
$2.4299
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.71 | 12.31M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
Lucid Diagnostics finalizes public offering of common stock - Medical Buyer
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - The Bradford Era
Lucid Diagnostics Closes $16.1 Million Public Offering - MSN
PAVmed (PAVM) Stock Price, News & Analysis - MarketBeat
PAVmed subsidiary completes $16.1M stock offering By Investing.com - Investing.com Canada
PAVmed subsidiary completes $16.1M stock offering - Investing.com Australia
Lucid Diagnostics completes $16.1 million stock offering By Investing.com - Investing.com South Africa
Lucid Diagnostics Raises $16.1 Mln Through Public Offering To Support Corporate Growth - Nasdaq
Lucid Diagnostics Announces Closing of Public Offering of Common Stock - GuruFocus
Lucid Diagnostics completes $16.1 million stock offering - Investing.com Australia
Lucid Diagnostics Raises $16.1M: Cancer Detection Company Strengthens Financial Position - Stock Titan
Indo-Asian News Service - Indo-Asian News Service (IANS)
Lucid Diagnostics Announces Proposed Public Offering of Common Stock - The Malaysian Reserve
Lucid Diagnostics announces proposed public offering of common stock - MSN
Medical Diagnostics Pioneer Lucid Secures $15M Strategic Financing Round - Stock Titan
Lucid Diagnostics plans stock offering to boost capital By Investing.com - Investing.com South Africa
Lucid Diagnostics Announces Proposed Public Offering of Common S - GuruFocus
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Lucid Diagnostics plans stock offering to boost capital - Investing.com Australia
Commercial-Stage Cancer Prevention Company Lucid Diagnostics Unveils Strategic Funding Move - Stock Titan
Indo-Asian News Service-LUCID DIAGNOSTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK - Indo-Asian News Service (IANS)
Indo-Asian News Service-LUCID DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK - Indo-Asian News Service (IANS)
PAVmed (PAVM) Files to Sell 3.3 Million Shares - GuruFocus
Pavmed Inc Files For Offering Of 3.3 Million Shares Of Common Stock - marketscreener.com
PAVmed stock touches 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
PAVmed stock touches 52-week low at $0.56 amid market challenges - Investing.com India
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Lucid Diagnostics to Participate in Fireside Chat at the 24th An - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
PAVmed outlines strategic milestones for 2025, including Veris implantable device submission - MSN
Pavmed’s Strategic Growth and Financial Challenges - MSN
PAVmed Inc. (NASDAQ:PAVM) Q4 2024 Earnings Call Transcript - Insider Monkey
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology - PR Newswire
Game-Changing Cancer Detection: EsoCheck Achieves 99% Accuracy Across 30,000 Patient Study - Stock Titan
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability - Yahoo
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Gr - GuruFocus.com
PAVmed Reports Strong Q4 Results and Strategic Progress - TipRanks
Earnings call transcript: PAVmed Q4 2024 reports net income boost - Investing.com India
Earnings call transcript: PAVmed Q4 2024 reports net income boost By Investing.com - Investing.com South Africa
PAVmed Inc Surpasses Q4 2024 Revenue Estimates with $1.2 Million, Driven by Record EsoGuard Test Volume - GuruFocus
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Placera.se
PAVmed Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PAVmed Achieves Triple Win: Record Tests, Insurance Coverage, Positive Income - Stock Titan
Lucid Diagnostics Reports Strong Growth and Future Plans - TipRanks
Lucid Diagnostics Provides Business Update and Reports Fourth Qu - GuruFocus
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):